Experiences with
Tarceva102 public posts
(FDA) approved the combination of Cyramza (ramucirumab) and Tarceva (erlotinib) for the first line treatment of advanced NSCLC
The FDA based their approval on the results of the clinical trial RELAY which showed that patients receiving Cyramza and Tarceva went longer periods of time without progression and their response to treatment lasted longer than those receiving Tarceva by itself.
Want to take advantage of all our features? Just log in!
or